Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05450965 · ClinicalTrials.gov registry record · Phase 2
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
A Phase 2 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 2
- Study locations
NCT05450965 is a Phase 2 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 37 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05450965, a Phase 2 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Conditions Studied
Interventions
- DRUG Onvansertib
Study Locations (2)
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05450965
The ClinicalTrials.gov registry entry for NCT05450965 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Onvansertib is the first listed.
NCT05450965 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05450965 about?
NCT05450965 is a clinical study titled "Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer". This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expresse...
What is the current status of trial NCT05450965?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2022-07-19. Estimated completion is 2027-11-30.
What conditions does trial NCT05450965 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05450965?
The interventions under investigation include: Onvansertib (DRUG).
Who is sponsoring clinical trial NCT05450965?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05450965 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.